A new blood test may detect Alzheimer’s disease years before symptoms appear, according to recent research.
The test focuses on a biomarker called pTau217, which can reveal early buildup of amyloid and tau proteins in the brain—key indicators of Alzheimer’s development. Researchers say this approach could offer a simpler, earlier alternative to current methods like PET scans, which are more expensive and less accessible.
The findings come from a study involving 317 participants aged 50 to 90, all of whom had normal cognitive function at the start. Over an average follow-up period of eight years, researchers analyzed blood samples alongside brain imaging and cognitive assessments to track changes linked to the disease.
Another study highlighted in the research suggests that a different protein, beta-synuclein, may also serve as an early warning sign. In that analysis of 178 individuals, elevated levels of this protein were found in people with genetic risk factors for Alzheimer’s, even before any symptoms emerged—potentially signaling risk up to 11 years in advance.
Experts note that detecting Alzheimer’s this early could open doors for timely intervention, allowing patients and families to plan ahead and potentially benefit from future treatments aimed at slowing disease progression.
While the results are promising, researchers emphasize that further validation is needed before such tests can be widely used in clinical settings. Still, the ability to identify biological signs of Alzheimer’s through a routine blood draw represents a significant step forward in the fight against the disease.
